An FDA committee is meeting today to discuss an application from Madison-based Exact Sciences to market its colorectal cancer screening test.
The Molecular and Clinical Genetics Panel has an all-day meeting scheduled in Maryland, with a vote set for 3:30 p.m. Central time.
The NASDAQ halted trading of the company’s stock this morning in advance of the panel, as it often does.